A Phase 3 interventional study of Paliperidone palmitate in Schizophrenia, sponsored by Janssen Pharmaceutical K.K.. Completed at 29 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-06-24.
Sponsored by Janssen Pharmaceutical K.K. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.
Among the 115 studies testing paliperidone in Schizophrenia, this one is the 51st largest by enrollment, is one of 8 that started in 2010, is one of 41 in phase 3, and was the 60th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Sites in China
Ages 18–65
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
Alejandro Alva · Sites in United States
Ages 18–65
Jiangsu Province Nanjing Brain Hospital · Sites in China
Ages 18–65
Sher-E-Bangla Medical College · Sites in Bangladesh
Ages 18–60
By country, each count listing its studies:
paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
115 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 7 · Phase 3 42 · Phase 4 42
First in 2003; this study’s year is marked. 8 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 201 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 178 across the 115 interventional studies. Of the 104 that completed or were terminated, 42 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
93 of 115 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Pharmaceutical K.K., one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Pharmaceutical K.K. is the lead sponsor of 126 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 7 (50%) have results posted.
206 studies in Schizophrenia by Johnson & Johnson: 2 open now, 2 under way, 1 of them phase 3. Of 203 finished, 57 (28%) have results posted.
Among the 206 studies in Schizophrenia by Johnson & Johnson, this one is the 78th largest by enrollment of the 176 interventional ones that give a count, is one of 13 that started in 2010, is one of 74 in phase 3, and was the 144th registered.
Johnson & Johnson’s Schizophrenia studies by the year they started, since 1996.
2 of the studies testing paliperidone in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07493551CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.A Bioequivalence Study of PP3M in Patients With Schizophrenia | 2026-12-31 |
| NCT04478838Centre for Addiction and Mental Health"Extended" (Alternate Day) Antipsychotic Dosing | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 115 studies testing paliperidone in Schizophrenia, from their registry updates:
Among Johnson & Johnson’s 206 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the long-term safety and tolerability of paliperidone palmitate in Japanese patients with schizophrenia. Secondary objectives of this study are to: explore the efficacy on symptoms of schizophrenia and the maintenance of treatment effect; explore the pharmacokinetics of paliperidone palmitate through sparse pharmacokinetic sampling.
This is an open-label, flexible-dose, multicenter study. The study will consist of 3 periods: an up-to-2-week pre-observation (screening) period, an observation period from Day 1 (baseline) to Week 49 (end of observation period) assessment, and a post-observation period from after the Week 49 (end-of-observation period) assessment to Week 57. For the patients who discontinue the study before the last assessment in Week 49, the post observation period will start after the discontinuation from observation period assessment with follow-up visits at 4, 8, and 12 weeks after the last injection. The total duration of the study will be 57 weeks, including the observation and post observation periods. Approximately 200 men and women, aged 20 years or older who meet the DSM-IV-TR criteria for schizophrenia at least 1 year before screening and have a Positive and Negative Syndrome Scale (PANSS) total score of 60 to 120 at screening and baseline will be enrolled, so that at least 100 patients complete this 1-year study. The patients who have a primary active Axis I disorder other than schizophrenia will not be enrolled in the study. Eligible patients will be administered an initial loading dose of paliperidone palmitate 150 mg eq. im on Day 1 and 100 mg eq. 1 week later in the deltoid muscle. The study drug will be administered in a flexible dose range of 25 to 150 mg eq. at 4-week intervals from Week 5 as either deltoid or gluteal muscle injections for a total of 11 injections. A dose of 75 mg eq. is recommended from Week 5 until Week 45. The study drug will be administered by a study drug manager and/or injector. Each dose increase should be in increments of 50 mg eq. or less. Dose increases can be considered if there is an increase in the PANSS total score (individual items or the total) or the Clinical Global Impression - Severity (CGI-S) score from the preceding assessment. Dose decreases can be considered if adverse events occur that appear to have a causal relationship with the investigational drug. The injection site (deltoid or gluteal) will, in principle, be fixed at the fourth injection and thereafter, but injection in the deltoid or gluteal muscle can be alternated at the discretion of the investigator if considered appropriate for the patient's safety. If repeated injections are administered in either the deltoid or gluteal muscles, then alternating the side of each injection (left or right) is recommended. The choice of injection needle will be determined by the patient's weight and by the injection site. The weight at baseline (Day 1) will be used when choosing needles for injection from Day 1 to Week 21, and the weight at Week 25 will be used when choosing needles for injection at Week 25 and thereafter. Patients weighing less than 200 lb (\<90 kg) will receive their deltoid injection with a 1-inch needle (23 G×1"). Patients weighing 200 lb or more (=90 kg), will receive their deltoid injection with a 1.5-inch needle (22 G×1 1/2"). All gluteal injections will be administered with a 1.5-inch needle (22 G×1 1/2"). The sponsor will collect adverse events starting with the signing of the informed consent form until completion of all end-of-study procedures. Adverse events will be followed by the investigator until it recovers or is considered clinically stable. Adverse events include any occurrence that is new in onset or aggravated in severity or frequency from the baseline condition, or abnormal results of diagnostic procedures, including laboratory test abnormalities. Blood samples (preferably fasted), for serum chemistry and hematology and a random urine sample for urinalysis, electrocardiogram (ECG), vital signs, height, weight, waist circumference, Body Mass Index (BMI), Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS), Columbia-Suicide Severity Rating Scale (C-SSRS), evaluation of the injection site and Visual Analog Scale (VAS) for patient's assessment of injection pain will be also collected for safety evaluation. PANSS total score and CGI-S score will be collected for efficacy evaluation. Samples for pharmacokinetic evaluation will be collected at designated timepoints. An optional 10-mL pharmacogenomic blood sample will be collected from patients who provide a separate written informed consent for this part of the study. The patients will receive paliperidone palmitate intramuscular (im) as an initial loading dose of 150 mg eq. on treatment Day 1 and 100 mg eq. 1 week later in the deltoid muscle. The study drug will be administered in a flexible dose range of 25 to 150 mg eq. at 4-week intervals from Week 5 as either deltoid or gluteal muscle injections for a total of 11 injections. A dose of 75 mg eq. is recommended from Week 5 until Week 45.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Paliperidone palmitate Paliperidone palmitate will be administered im as an initial loading dose of 150 mg eq. on Day 1 and 100 mg eq. 1 week later in the deltoid muscle and will be administered in a flexible dose range of 25 to 150 mg eq. at 4-week intervals from Week 5 for a total of 11 injections.
Drug: Paliperidone palmitate
Paliperidone palmitate will be administered im as an initial loading dose of 150 mg eq. on Day 1 and 100 mg eq. 1 week later in the deltoid muscle, and will be administered in a flexible dose range of 25 to 150 mg eq. at 4-week intervals from Week 5 for a total of 11 injections.
Incidence of adverse events as a measure of safety and tolerability
Time frame: 49 Weeks
The change from baseline in Positive and Negative Syndrome Scale (PANSS) total score
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
Time frame: Baseline, Week 49
The change from baseline in Clinical Global Impression - Severity (CGI-S) score
The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a patient. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill patients". Higher scores indicate worsening.
Time frame: Baseline, Week 49
Pharmacokinetic evaluations (graphically display to explore dose proportionality and achievement of steady state)
Time frame: 49 Weeks (Baseline, Week 1, 5, 9, 13, 21, 25, 37, 45, 47 and 49)
The record gives a start of Oct 2010, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Paliperidone